Objective. We hypothesize that treatment with Pravastatin, a HMG CoA reductase inhibitor would improve flow-mediated dilation (FMD), a nitric oxide dependent phenomenon and the earliest detectable marker of endothelial dysfunction, in asymptomatic patients with type-1 diabetes. Materials and methods. FMD of the brachial artery in response to reactive hyperaemia was measured using high-resolution ultrasonograghy. Young male patients with type-1 diabetes (n=9) were compared with age matched non-diabetic controls (n=8). Results. The FMD response in the control group was a median increase in diameter of 7.9 (range 3.8–12.6)%. In the diabetic group the FMD response was impaired when compared with controls with a median increase only of 4.4 (range 3.7–5.8)% (p
